Advanced search
Publication Cover
HIV Therapy Volume 4, 2010 - Issue 5
Journal homepage
22
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The Impact of Baseline Characteristics on Virologic Response to Etravirine: 48-Week Pooled Analysis of Duet-1 and Duet-2

Pedro Cahn7 Fundación Huesped, Angel Peluffo3932, Buenos Aires, C1202ABB, Argentina. [email protected]Correspondence[email protected]
View further author information
,
Richard Haubrich1 University of California San Diego, San Diego, CA, USAView further author information
,
Christine Katlama2 Université Pierre et Marie Curie, Paris VI, and Hôpital Pitié-Salpêtrière, Paris, FranceView further author information
,
Frank Goebel3 Ludwig Maximilian University, Munich, GermanyView further author information
,
Fredy Suter4 Division of Infectious Diseases, Ospedali Riuniti, Bergamo, ItalyView further author information
,
Monika Peeters5 Tibotec BVBA, Beerse, BelgiumView further author information
,
Johan Vingerhoets5 Tibotec BVBA, Beerse, BelgiumView further author information
,
Rekha Sinha5 Tibotec BVBA, Beerse, BelgiumView further author information
&
James Witek6 Tibotec Inc., Titusville, NJ, USAView further author information
 show all
Pages 605-610 | Published online: 25 Oct 2010

Bibliography

  • Langford SE , AnanworanichJ, CooperDA: Predictors of disease progression in HIV infection: a review.AIDS Res. Ther.14, 4–11(2007).
  • Phillips AN , LundgrenJD: The CD4 lymphocyte count and risk of clinical progression.Curr. Opin. HIV AIDS1, 43–49(2006).
  • Katlama C , HaubrichR, LalezariJet al.: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled week 48 analysis of two randomized, controlled trials.AIDS23, 2289–2300(2009).
  • Katlama C , ClotetB, MillsAet al.: Efficacy and safety of etravirine at week 96 in treatment-experienced HIV-1-infected patients in the DUET-1 and DUET-2 trials.Antivir. Ther. (2010) (In press).
  • Madruga JV , CahnP, GrinsztejnBet al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.Lancet370, 29–38(2007).
  • Lazzarin A , CampbellT, ClotetBet al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.Lancet370, 39–48(2007).
  • Cahn P , Molina J-M, Towner W et al.: 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virologic response to etravirine. Presented at: XVII International AIDS Conference. Mexico City, Mexico, 3–8 August (2008) (Abstract TUPE0047).
  • Trottier B , Di PerriG, MadrugaJVet al.: Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. HIV Clin. Trials (2010) (In press).
  • Vingerhoets J , AzijnH, FransenEet al.: TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.J. Virol.79, 12773–12782(2005).
  • Vingerhoets J , AzijnH, TambuyzerLet al.: Activity of etravirine on different HIV-1 subtypes: in vitro susceptibility in treatment-naïve patients and week 48 pooled DUET study data.AIDS Res. Hum. Retroviruses26, 621–624(2010).
  • Katlama C , GirardPM, JunodPet al.:Etravirine demonstrates favorable efficacy and safety in the Phase III DUET trials regardless of geographic location. Presented at: HIV DART: Frontiers in Drug Development for Antiretroviral Therapies.Rio Grande, Puerto Rico, 9–12 December (2008) (Abstract 52).
  • Mills A , CahnP, Molina J-M et al.: Etravirine (ETR; TMC125) demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July (2009) (Abstract MOPEB036).
  • Cooper DA , SteigbigelRT, GatellJMet al.: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.N. Engl. J. Med.359, 355–365(2008).
  • Fätkenheuer G , NelsonM, LazzarinAet al.: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.N. Engl. J. Med.359, 1442–1455(2008).
  • Clotet B , BellosN, Molina J-M et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet369, 1169–1178(2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.